
I am delighted to share that the results of the INTerpath-001 trial have been published in the @NEJM. It was a privilege to lead this study as first author and chair of the steering committee, together with medical oncology colleagues from around the world and at @MelanomaAus. The trial tested a personalised therapeutic cancer vaccine, as distinct from a preventative vaccine, combined with pembrolizumab. It was given to people with melanoma who had already had surgery but were at high risk of the cancer coming back. The therapy is made for each person, based on the changes found in their own tumour. Adding the personalised therapy to pembrolizumab reduced the risk of the cancer returning or of death by 58% compared with pembrolizumab alone, from 6 months after the start of therapy. This result rests on science, and science rests on facts. It stands on more than a century of incremental discovery and innovation, with each generation building on the last. What I love most is the spirit of exploration: we never assume we have it right, and we keep learning and refining. Go #science! None of this would be possible without the patients and families who took part, and the teams at every site who worked so generously together across many countries. Thank you to everyone involved. This is what global collaboration looks like, and I am so grateful to be part of it. Read the full paper > bit.ly/48IDpk8 #intismeran #CancerVaccine @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @NthSydHealth @ausoftheyear































